Pure Global

A Phase I/II, Multicenter, Open-Label, PK, Safety and Efficacy Study to Evaluate Raltegravir in HIV-1 Infected Youth - Trial 2009-015884-15

Access comprehensive clinical trial information for 2009-015884-15 through Pure Global AI's free database. This phase not specified trial is sponsored by The National Institute of Allergy and Infectious Diseases (NIAID) and The Eunice Kennedy Shriver NICHD and is currently status unknown. The study focuses on HIV.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to EU Clinical Trials Register data, helping medical device and pharmaceutical companies navigate clinical research efficiently.

Free Database
Powered by Pure Global AI
840K+ Trials
2009-015884-15
Trial Details
EU Clinical Trials Register • 2009-015884-15
Pure Global
DJ Fang

DJ Fang

MedTech Regulatory Expert

Need help with 30+ markets registration?

Pricing
A Phase I/II, Multicenter, Open-Label, PK, Safety and Efficacy Study to Evaluate Raltegravir in HIV-1 Infected Youth

Study Focus

HIV

Sponsor & Location

The National Institute of Allergy and Infectious Diseases (NIAID) and The Eunice Kennedy Shriver NICHD

Timeline & Enrollment

N/A

N/A

N/A

Primary Outcome

•Known ≥ Grade 3 of any of the following laboratory tests within 30 days prior to study entry: neutrophil count, hemoglobin, platelets, AST, ALT, lipase, serum creatinine.

ICD-10 Classifications

HIV disease resulting in other viral infections
Human immunodeficiency virus [HIV] disease
HIV disease resulting in other bacterial infections
Acute HIV infection syndrome
Unspecified human immunodeficiency virus [HIV] disease

Data Source

EU Clinical Trials Register

2009-015884-15

Non-Device Trial